Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Exchange Rates
Interest Rates
Economy
Global Metrics

Genetic Technologies Gross Margin 2010-2022 | GENE

Current and historical gross margin for Genetic Technologies (GENE) over the last 10 years. The current gross profit margin for Genetic Technologies as of December 31, 2022 is %.
  
Genetic Technologies Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.022B $0.005B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00